Lacosamide Medical Valley 100 mg নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

lacosamide medical valley 100 mg

medical valley invest ab - lakosamid - tablett, filmdrasjert - 100 mg

Lacosamide Medical Valley 50 mg নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

lacosamide medical valley 50 mg

medical valley invest ab - lakosamid - tablett, filmdrasjert - 50 mg

Lacosamide Medical Valley 150 mg নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

lacosamide medical valley 150 mg

medical valley invest ab - lakosamid - tablett, filmdrasjert - 150 mg

Lacosamide Medical Valley 200 mg নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

lacosamide medical valley 200 mg

medical valley invest ab - lakosamid - tablett, filmdrasjert - 200 mg

Vimpat 100 mg নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

vimpat 100 mg

orifarm as - lakosamid - tablett, filmdrasjert - 100 mg

Vimpat 150 mg নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

vimpat 150 mg

orifarm as - lakosamid - tablett, filmdrasjert - 150 mg

Vimpat 200 mg নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

vimpat 200 mg

orifarm as - lakosamid - tablett, filmdrasjert - 200 mg

Vimpat 50 mg নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

vimpat 50 mg

orifarm as - lakosamid - tablett, filmdrasjert - 50 mg

Vimpat ইউরোপীয় ইউনিয়ন - নরওয়েজীয় - EMA (European Medicines Agency)

vimpat

ucb pharma sa - lakosamid - epilepsi - antiepileptics, - vimpat er indisert som monoterapi og tilleggsbehandling ved behandling av partielle anfall med eller uten sekundær generalisering hos voksne, ungdom og barn fra 4 år med epilepsi.

Lacosamide Accord ইউরোপীয় ইউনিয়ন - নরওয়েজীয় - EMA (European Medicines Agency)

lacosamide accord

accord healthcare s.l.u. - lakosamid - epilepsi - antiepileptics, - lacosamide accord is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. lacosamide accord is indicated as adjunctive therapy•         in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. •         in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.